Fundraising Fox
/Companies
Sign in

Vascular Perfusion Solutions

San Antonio, US · Founded 2016 · Delaware corporation

Find your way into Vascular Perfusion Solutions

94 people in our graph share verified history with the Vascular Perfusion Solutions team — schools, employers, funds. One of them is your warm intro.

D. Dawn Bitzunlockedknows Leon Bunegin · together at Vascular Perfusion Solutions (overlapped)
×7knows the team · via Medical University of South Carolina
×4knows the team · via UT Health San Antonio

Vascular Perfusion Solutions develops the VP.S ENCORE, a portable cardiac perfusion system using a blood-free perfusate to extend donor heart viability up to 8 hours for transplant recovery teams. The investigational medical device is in preclinical evaluation under FDA Breakthrough Device Designation.

BiotechHealthtechMedical Devices

Founders & leadership

Vascular Perfusion Solutions was founded in 2016 by Rafael Veraza, Leon Bunegin, and Leonid Bunegin.

RV
Rafael VerazaCo-founder · Chief Executive Officer & PresidentRafael Veraza is CEO and President of Vascular Perfusion Solutions, a medical device company developing portable cardiac perfusion technology. He advanced through roles at the company to lead its FDA Breakthrough Device Designation and commercialization efforts, with background spanning life sciences, biotech, and medtech startups.
LBLeon Bunegin
Leon BuneginCo-Founder and Chief Innovation Officer
LBLeonid Bunegin
Leonid BuneginCo-Founder and Chief Innovation OfficerHe spent more than four decades at UT Health San Antonio as a tenured associate professor in the School of Medicine and later the Graduate School of Biomedical Sciences, following early work as a research assistant professor in the Division of Neurosurgery at the University of Pittsburgh. He co-founded the company in 2022 and serves as its Chief Innovation Officer.
CT
C. Thomas MayesExecutive
TH
Toni HaenninenExecutive
KAKristina Andrijauskaite
Kristina AndrijauskaiteChief Scientific & Technology OfficerKristina Andrijauskaite is Chief Scientific & Technology Officer at Vascular Perfusion Solutions, where she leads development of oxygenated machine perfusion platforms for organ preservation. She has approximately 20 years of multidisciplinary research experience in organ preservation, oncology, and space biology, including work as a lead scientist on suborbital space missions and selection as an astronaut candidate by the European Space Agency.
TDTom DeBrooke
Tom DeBrookeChairman of the Boardformer
RV
Rafael Veraza, PhD, MPhChief Executive Officer & PresidentRafael Veraza holds a PhD and MPH and has worked in medical device and biotech ventures. He became CEO and President of Vascular Perfusion Solutions in 2022, overseeing development of a cardiac perfusion system that received FDA Breakthrough Device Designation.
MM
Mark MullerNamed on SEC filing
KW
Klaus WeiswurmNamed on SEC filing

Board

CJ
Celia JairalaBoard director

Funding

SEC filings, press & company announcements

$154.9M disclosed across 8 of 9 rounds · 2019–2025

▶$147MraisedMay 2025 · 21 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • C. Thomas MayesExecutive Officer, Director
  • Rafael VerazaExecutive Officer, Director
  • Toni HaenninenExecutive Officer
  • Celia JairalaDirector
  • Leon BuneginExecutive Officer, Director
  • Kristina AndrijauskaiteExecutive Officer
Offering amount
$343.8M
Amount sold
$147M
First sale
May 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$500KraisedJun 2023 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Rafael VerazaExecutive Officer, Director
  • Paul PerryExecutive Officer
  • Klaus WeiswurmDirector
  • Tom DeBrookeExecutive Officer, Director
  • Leon BuneginDirector
  • Mark MullerDirector
  • Celia JairalaDirector
Offering amount
$2.5M
Amount sold
$500K
First sale
May 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$500KraisedMay 2022 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Klaus WeiswurmDirector
  • Mark MullerExecutive Officer, Director
  • Tom DeBrookeExecutive Officer, Director
  • Celia JairalaDirector
  • Leon BuneginDirector
  • Paul PerryExecutive Officer
Offering amount
$5M
Amount sold
$500K
First sale
May 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$850KraisedNov 2021 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Leon BuneginExecutive Officer, Director
  • Mark MullerExecutive Officer, Director
  • Klaus WeiswurmDirector
  • Tom DeBrookeExecutive Officer, Director
  • Celia JairalaDirector
  • Paul PerryExecutive Officer
Offering amount
$3M
Amount sold
$850K
First sale
Oct 2021
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.1MraisedAug 2021 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Leon BuneginExecutive Officer, Director
  • Celia JairalaDirector
  • Paul PerryExecutive Officer
  • Tom DeBrookeExecutive Officer, Director
  • Mark MullerExecutive Officer, Director
  • Klaus WeiswurmDirector
Offering amount
$3M
Amount sold
$1.1M
First sale
Jul 2021
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.4MraisedAug 2020 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Tom DeBrookeExecutive Officer, Director
  • Paul PerryExecutive Officer
  • Leon BuneginDirector
  • Celia JairalaDirector
  • Mark MullerExecutive Officer, Director
  • Klaus WeiswurmDirector
Offering amount
$2.5M
Amount sold
$2.4M
First sale
Aug 2020
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$602.4KraisedOct 2019 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Tom DeBrookeExecutive Officer, Director
  • Leon BuneginDirector
  • Mark MullerExecutive Officer, Director
  • Klaus WeiswurmDirector
  • Paul PerryExecutive Officer
  • Celia JairalaDirector
Offering amount
$1.5M
Amount sold
$602.4K
First sale
Oct 2019
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedJun 2019 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Leon BuneginDirector
  • Mark MullerDirector
  • Klaus WeiswurmDirector
  • Tom DeBrookeExecutive Officer, Director
  • Celia JairalaDirector
Offering amount
$8M
Amount sold
$2M
First sale
Jun 2019
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap
Rf Surgical11 shared keywordsMedtronic is a healthcare technology company that develops medical devices and technologies — including pacemakers, robotic-assisted surgery systems, and AI-driven health tools — used by doctors, scientists, and engineers to treat pain and disease. It works with clinicians to create solutions aimed at treating conditions such as AFib.
Paragonix Technologies10 shared keywordsParagonix Technologies develops, manufactures, and services organ preservation devices that combine cooling techniques with digital tracking and monitoring for clinicians managing donor organs during transplantation. It also maintains the GUARDIAN clinical registries, a database of organ preservation and post-transplant outcome data, serving the organ transplant industry.
Organ Recovery10 shared keywordsOrgan Recovery Systems develops organ preservation products and services, including machine perfusion technology for donor kidneys, for transplant programs and transplant professionals. The company supports over 400 transplant programs across 49 countries and also provides clinical and technical support services.

Companies competing with Vascular Perfusion Solutions for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Vascular Perfusion Solutions do?
Vascular Perfusion Solutions develops the VP.S ENCORE, a portable cardiac perfusion system using a blood-free perfusate to extend donor heart viability up to 8 hours for transplant recovery teams. The investigational medical device is in preclinical evaluation under FDA Breakthrough Device Designation.
Who founded Vascular Perfusion Solutions?
Vascular Perfusion Solutions was founded by Rafael Veraza, Leon Bunegin, Leonid Bunegin in 2016.
How much funding has Vascular Perfusion Solutions raised?
Vascular Perfusion Solutions has disclosed $154.9M raised across 8 of its 9 known rounds.
Where is Vascular Perfusion Solutions headquartered?
Vascular Perfusion Solutions is headquartered in San Antonio, US.